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CORRESPONDENCE
Letters to the Editor
Angiotensin-Converting Enzyme Inhibitors
and Outcome Among Patients With
Heart Failure and Renal Insufficiency:
Need for a Prospective Study
Ezekowitz et al. (1) recently reported lack of benefit of
angiotensin-converting enzyme (ACE) inhibitors on mortality in
patients with chronic heart failure (CHF) in whom estimated
creatinine clearance was below 60 ml/min, as opposed to a
beneficial effect in those with creatinine clearance above 60
ml/min. The researchers attribute this lack of benefit to a possible
interaction between aspirin and ACE inhibitor use, suggesting that
aspirin might blunt the effects of ACE inhibitors. Whereas this
might be true, in our opinion another explanation should be
considered as well, namely prescription bias. In CHF, ACE
inhibition should be prescribed to all patients, especially in those
with severe CHF. Regretfully, this is not always true in daily
practice.
In the cohort studied by Ezekowitz et al. (1), only 60% were
using ACE inhibitors. It has been reported that physicians are
reluctant to prescribe ACE inhibitors in the presence of severe
renal dysfunction (2). Physicians are more willing to prescribe
ACE inhibitors to CHF patients if such patients are more
symptomatic (3). In CHF, renal function impairment can elicit a
clinically more unstable condition—for instance, by fluid retention.
Accordingly, in the present study by Ezekowitz et al. (1), con-
founding by prescription may have occurred among the patients
with renal function impairment, with ACE inhibitors being
preferentially prescribed to subjects with a more unstable cardiac
condition and a worse prognosis.
In view of the prognostic importance of renal function in
subjects with CHF, it might be relevant that, in subjects with
primary renal disease and severely impaired renal function, ACE
inhibition protects against further worsening of renal function (4).
Whether this might be of benefit in CHF patients has not been
studied so far. Taken together, the data by Ezekowitz et al. (1)
argue for prospective studies into the role of ACE inhibitors in
CHF subjects with renal function impairment.
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Beta-Blockers Versus Digoxin to Control
Ventricular Rate During Atrial Fibrillation
The recent study of Olshansky et al. (1) investigated the approaches
used to control rate, the effectiveness of rate control, and changeovers
from one drug class to another in the Atrial Fibrillation Follow-up
Investigation of RhythmManagement (AFFIRM) study. Comparing
the cumulative achievement of adequate ventricular rate control and
the time to discontinuation of rate-control therapy, the investigators
concluded that beta-blockers were the most effective drugs. We
believe the superiority of beta-blockers over other therapeutic options,
particularly over digoxin, must be interpreted with caution.
Adequate ventricular rate control was cumulatively obtained in
a similar proportion of patients taking beta-blockers alone and
digoxin alone (59% vs. 58%, respectively), a result that was
confirmed both during rest (68% for both therapies) and with
exertion (72% vs. 70%, respectively). Afterwards, the researchers
considered beta-blockers more effective, observing that, over time,
more patients taking digoxin or a calcium channel blocker were
changed to another drug (p  0.0001). However, in this compar-
ison, the group of patients using beta-blockers and calcium
channel antagonists included those taking digoxin concomitantly,
whereas the digoxin group included only individuals using this
drug alone. It is possible to observe that, in patients using
beta-blockers, the association of digoxin increased the proportion
of adequate rate control from 59% to 70%, and this increment may
have led to the observed superiority with beta-blocker therapy.
Randomized studies have already demonstrated that the associa-
tion of digoxin with beta-blockers is more effective than beta-
blockers alone in this setting (2,3).
In their discussion, the investigators (1) stated that “because no
placebo control was used in this trial, it is possible that no
medication would have worked as well as digoxin did to control the
rate.” Because the randomization of the AFFIRM trial was not
performed to compare drugs to control ventricular rate, this
observation should not be restricted to digoxin. The concept that
oral digoxin is efficient in controlling ventricular rate during atrial
fibrillation is well accepted (4), despite being supported more by
studies that demonstrated the reduction of ventricular rate after the
initiation of the therapy (5) than by the sparse number of
randomized placebo-controlled trials (6).
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